{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:53:02Z","timestamp":1753883582409,"version":"3.41.2"},"reference-count":16,"publisher":"The Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We report a case of persistent gynecomastia in a healthy 20-year-old man after 1 month of low-dose finasteride. Finasteride was discontinued after 2 months, and gynecomastia was unchanged 5 months after drug withdrawal. The gynecomastia regressed but did not resolve after 6 months of treatment with raloxifene, a selective estrogen receptor modulator. One year later, bilateral mammoplasty was performed to remove the remaining breast tissue. Finasteride, a 5-alpha-reductase inhibitor, is widely used for the treatment of androgenetic alopecia. Gynecomastia is an expected side effect of this therapy given its mechanism of action. However, only 8 cases of gynecomastia have been reported with low-dose (1\u2005mg daily) finasteride treatment since its approval for androgenetic alopecia in 1997. This raises the concern that gynecomastia resulting from low-dose finasteride is significantly underreported, causing inadequately informed patients. Further, because of the risk of gynecomastia, it is important for prescribing physicians to counsel patients regarding this complication and to consider early intervention when finasteride-induced gynecomastia first arises to prevent fibrosis and thus irreversible gynecomastia.<\/jats:p>","DOI":"10.1210\/jcemcr\/luae050","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T08:05:57Z","timestamp":1713945957000},"source":"Crossref","is-referenced-by-count":2,"title":["Persistent Gynecomastia due to Short-term Low-dose Finasteride for Androgenetic Alopecia"],"prefix":"10.1210","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0018-6172","authenticated-orcid":false,"given":"Hal Steven","family":"Farkas","sequence":"first","affiliation":[{"name":"College of Osteopathic Medicine, Nova Southeastern University , Fort Lauderdale, FL 33328, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7227-5925","authenticated-orcid":false,"given":"Youn Hee","family":"Jee","sequence":"additional","affiliation":[{"name":"Children's National Hospital, Endocrinology and Diabetes , Washington, DC 20010, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3513-1671","authenticated-orcid":false,"given":"Vivian","family":"Szymczuk","sequence":"additional","affiliation":[{"name":"National Institute of Dental and Craniofacial Research, National Institutes of Health , Bethesda, MD 20892, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2594-9955","authenticated-orcid":false,"given":"Ellen Werber","family":"Leschek","sequence":"additional","affiliation":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD 20892, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"issue":"3","key":"2024052407034664200_luae050-B1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1515\/HMBCI.2010.035","article-title":"Human type 3 5\u03b1-reductase is expressed in peripheral tissues at higher levels than types and 2 and its activity is potently inhibited by finasteride and dutasteride","volume":"2","author":"Yamana","year":"2010","journal-title":"Horm Mol Biol Clin Investiq"},{"issue":"6","key":"2024052407034664200_luae050-B2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/MED.0000000000000116","article-title":"5-Alpha reductase deficiency: a 40-year retrospective review","volume":"21","author":"Okeigwe","year":"2014","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2024052407034664200_luae050-B3"},{"key":"2024052407034664200_luae050-B4"},{"issue":"5","key":"2024052407034664200_luae050-B5","doi-asserted-by":"crossref","first-page":"e624","DOI":"10.1016\/j.clbc.2019.04.006","article-title":"Analysis of data from breast diseases treated with 5-alpha reductase inhibitors for benign prostatic hyperplasia","volume":"19","author":"Fang","year":"2019","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"2024052407034664200_luae050-B6","first-page":"55","article-title":"Reversible painful gynaecomastia induced by low dose finasteride (1\u2005mg\/day)","volume":"41","author":"Wade","year":"2000","journal-title":"Aust J Dermatol"},{"issue":"4","key":"2024052407034664200_luae050-B7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.5858\/2000-124-0625-CAIAYO","article-title":"Cytologic atypia in a 53-year-old man with finasteride-induced gynecomastia","volume":"124","author":"Zimmerman","year":"2000","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"2024052407034664200_luae050-B8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/archderm.138.4.533","article-title":"Unilateral gynecomastia induced by treatment with 1 mg of oral finasteride","volume":"138","author":"Ferrando","year":"2002","journal-title":"Arch Dermatol"},{"issue":"1","key":"2024052407034664200_luae050-B9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0974-7753.51930","article-title":"Finasteride induced gynecomastia: case report and review of the literature","volume":"1","author":"Ramot","year":"2009","journal-title":"Int J Trichology"},{"issue":"4","key":"2024052407034664200_luae050-B10","first-page":"550","article-title":"The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia","volume":"41","author":"Drake","year":"1999","journal-title":"J Am Acad Dermatol"},{"first-page":"1","volume-title":"Endotext [Internet]","author":"Swerdloff","key":"2024052407034664200_luae050-B11"},{"issue":"5","key":"2024052407034664200_luae050-B12","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1210\/jc.2006-2203","article-title":"The effect of 5\u03b1-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men","volume":"92","author":"Amory","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2024052407034664200_luae050-B13","first-page":"1","volume-title":"StatPearls [Internet]","author":"Kumar","year":"2024"},{"issue":"8","key":"2024052407034664200_luae050-B14","doi-asserted-by":"crossref","first-page":"597","DOI":"10.14423\/SMJ.0000000000001425","article-title":"An approach to gynecomastia in primary care clinics","volume":"115","author":"Bharathidasan","year":"2022","journal-title":"South Med J"},{"issue":"7","key":"2024052407034664200_luae050-B15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00066-020-01598-9","article-title":"Treatment strategies to prevent and reduce gynecomastia and\/or breast pain caused by antiandrogen therapy for prostate cancer: statement from the DEGRO working group prostate cancer","volume":"196","author":"Ghadjar","year":"2020","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"2024052407034664200_luae050-B16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1741-7015-10-96","article-title":"Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review","volume":"10","author":"Kunath","year":"2012","journal-title":"BMC Med"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/2\/5\/luae050\/57595442\/luae050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/2\/5\/luae050\/57595442\/luae050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T07:39:46Z","timestamp":1716536386000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luae050\/7657109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,4,23]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luae050","relation":{},"ISSN":["2755-1520"],"issn-type":[{"type":"electronic","value":"2755-1520"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,4,23]]},"article-number":"luae050"}}